Neurosci na gaba. 2014; 8: 26.
- An buga a kan layi na 2014 Feb 13. doi: 10.3389 / fnins.2014.00026
PMCID: PMC3923148
Emilio Merlo Pich 1, * da Sergio Melotto 2
Wasu labaran da ke cikin PMC sun ambaci wannan labarin .
Abstract
Shekaru goma sha biyar bayan ganowar hypocretin / orexin babban jigon shaida an tattara yana tallafawa muhimmiyar rawa a cikin tsarin tsarin ayyuka da yawa. Yayin da aka haɗu da matakan da muna haɓaka da hypocretin / orexin da narcolepsy, an haɓaka matakan da suka karu a cikin 'yan shekarun nan zuwa jihohi na jihohi na musamman, kuma musamman ga rashin barci. Shiga zuwa FDA na aboki mai sauƙi mai sauƙi mai sauƙi mai sauƙi (DORA) don nuna alamar rashin barci ya kara ƙarfafa irin wannan shaida. Duk da haka, kamar yadda tsinkaya cikin gaggawa ma yana da hankulan yanayin tashin hankali da tsoro, har ma da abstinence da sha'awar maganin rashin amfani. A cikin wannan bita muna taƙaita taƙaitaccen shaidar da ke taimakawa wajen ci gaba da karɓar mai karfin 1 (OX1) mai karɓar nau'in kwalliya. Gwaje-gwaje ta yin amfani da sakonnin OX1 SB-334867 da mutun mutun sun haɗa da mai karɓar OX1 a kafofin watsa labaran sake dawowa da miyagun kwayoyi na neman éthanol, nicotine, cocaine, cannabinoids da morphine. Kwanan nan, an samar da bayanai tare da rubutun da aka zaɓa na OX1 wadanda suka hada da GSK1059865 da ACT-335827 akan halayyar jiki da kuma amsawar zuciya na zuciya ga masu damuwa da masu haɗari a cikin dabbobi. A ƙarshe, yayinda ake jiran samfurin maganin maganin maganin maganin maganin ƙwayoyi a cikin mutane, hadarin da kuma amfani ga ci gaban wani mai karɓar mai karɓar mai karɓar OX1 don Ra'ayoyin Binge da Cutar Dama.
Gabatarwa
Hypocretin/orexin wani neuropeptide ne mai hana ƙwayoyin cuta wanda ya ƙunshi siffofi biyu, A da B, wanda ke ɗauke da amino acid 33 da 28 bi da bi, kuma yana ɗaurewa ga masu karɓar furotin guda biyu masu haɗin G, OX1 (ko hcrt-1) da OX2 (ko hcrt-2) (de Lecea et al., 1998 ; Sakurai et al., 1998 ).
Ana samar da hypocretin/orexin peptide a cikin ƙaramin adadin ƙwayoyin jijiyoyi da ke cikin yankin dorsomedial—perifornical hypothalamic area (DMH/PeF) da kuma a cikin hypothalamic nucleus na gefe (LH). Ana iya samun zare masu kyau na jijiyoyi da kuma ƙarshensu a wurare da dama na tsarin jijiyoyi na tsakiya da na gefe, gami da jijiyar vagus, kashin baya, tushen kwakwalwa, hypothalamus, thalamus, tsarin limbic, da wasu yankuna na cortical (Peyron et al., 1998 ; Heinonen et al., 2008 ). Masu karɓar OX/hcrt suna nuna irin wannan rarrabawa mai tsawo (Marcus et al., 2001 ), suna nuna yuwuwar rawar da hypocretins/orexins ke takawa a matsayin peptides masu daidaita ayyuka da dama da tsarin limbic ke sarrafawa (Johnson et al., 2012a , b ; Mahler et al., 2012 ; Boutrel et al., 2013 ; Tsujino da Sakurai, 2013 ).
Mai karɓar OX1 ya ƙunshi amino acid 425 yayin da mai karɓar OX2 ya ƙunshi amino acid 444 tare da kamanceceniya tsakanin masu karɓar guda biyu na kashi 68% (Sakurai et al., 1998 ). Duk da cewa masu karɓar biyu suna haɗuwa da Gq-protein, mai karɓar OX1 kawai yana haɗuwa da Gs-protein. Kunna mai karɓar yana ƙara matakan calcium a cikin ƙwayoyin halitta ta hanyar ƙaruwar inositol-1,4,5-triphosphate wanda Gq-dependent phospholipase C (PLC) ya haifar (Lund et al., 2000 ) da diacylglycerol, wanda ke haifar da kunna nau'in δ na protein kinase C, wanda daga ƙarshe ya shiga hanyar ERK phosphorylation (Ekholm et al., 2007 ).
Masu karɓar OX1 da OX2 suna rarrabawa daban-daban a cikin kwakwalwar dabbobi masu shayarwa (Marcus et al., 2001 ), suna daidaita rarrabawar tasirin hypocretin/orexin. An sami shaidar rarrabuwar masu karɓar guda biyu kwanan nan ta amfani da hoton maganadisu na maganin magunguna (phMRI) a cikin beraye. An rage tasirin kunnawa na amphetamine ta hanyar magani kafin a fara amfani da mai karɓar OX2 mai zaɓin JNJ-1037049 ko tare da sabon mai karɓar OX1 GSK1059865: JNJ-1037049 ya rage tasirin amphetamine a cikin cortex na gaba da thalamus, yankunan da ke da hannu a cikin tashin hankali, yayin da GSK1059865 ya rage kunnawa a cikin amygdala mai tsawo, BNST da ventral striatum; duk sassan kwakwalwa da ke da hannu a cikin damuwa da motsawa (Gozzi et al., 2011 ). Waɗannan bambance-bambancen a cikin taswira masu aiki, tare da bambance-bambancen a cikin bayanan halayen suna tallafawa dalili don bincika alamu daban-daban don sabbin hanyoyin warkewa waɗanda ke niyya ga masu karɓar OX1 ko OX2 da zaɓi. Duk da haka, yayin da rawar da mai karɓar OX2 ke takawa a cikin barci da tashin hankali ke takawa yana da ƙarfi ta hanyar shaidar gwaji da ake da ita (Gatfield et al., 2010 ), har yanzu ana kan tantance yuwuwar warkewa ta zaɓaɓɓen adawar mai karɓar OX1 (Gotter et al., 2012 ).
Fahimtar ilimin halittar tsarin hypocretin/orexin ya inganta shirye-shiryen gano magunguna a kamfanonin magunguna da dama, wanda ya haifar da jerin haƙƙin mallaka da mahaɗan da ke da halaye daban-daban na zaɓi da kuma in vitro (Faedo et al., 2012 ; Lebold et al., 2013 ). Kamar yadda aka nuna a sama, an yi amfani da wasu mahaɗan a matsayin kayan aikin likitanci don bincika hanyoyin sadarwa na OX1 da OX2 waɗanda ke dogara da su a cikin jiki . An sami nasarar ci gaba da amfani da mahaɗan kaɗan a cikin mutane, musamman magungunan OX1-OX2 masu karɓar amsawa guda biyu (DORA) almorexant (Hoever et al., 2012 ), SB-649868 (Bettica et al., 2012 ), da suvorexant (Herring et al., 2012 ). Suvorexant ne kawai ya sami nasara ta hanyar ci gaban Mataki na 3 kuma an shigar da shi a Amurka a matsayin sabon magani don rashin barci a cikin 2013.
Kayan aikin magani na farko da aka yi amfani da shi azaman antagonist na mai karɓar OX1 shine SB-334867 (Jones et al., 2001 ; Smart et al., 2001 ). Kwanan nan, an gabatar da wasu mahaɗan: GSK1059865 (Alvaro et al., 2009 ; Gozzi et al., 2011 ), 2,5 di-substituted piperidines (Jiang et al., 2012 ) da ACT-335827 (Steiner et al., 2013 ).
A cikin wannan bita muna magance shaidar, mafi yawancin an tattara tare da kayan aikin kantin magani, don aikin da ya dace da ƙananan yaduwar cutar OX1 a cikin halin da ake ciki, musamman ma dangane da jaraba da cin abinci, da kuma cikin damuwa.
Hypocretin / Eexin da kuma OX1 mai karɓar maganin ƙwayar cuta - kamar kuma cin abinci masu cin nama
Wasu bincike da aka gudanar kafin a fara aiki sun nuna cewa tsarin hypocretin/orexin yana da hannu a cikin halayen tilastawa da maimaitawa da kuma kula da halayen da suka shafi manufa. Sabbin bita masu kyau sun taƙaita shaidar da aka tattara a cikin labarai sama da ɗari waɗanda ke nuna cewa tsarin hypocretin/orexin a cikin hypothalamus na gefe (Harris et al., 2005 ) yana da hannu a cikin rikice-rikicen ɗabi'a masu kama da jaraba da ke da alaƙa da fallasa ga cocaine, amphetamine, morphine, heroin, nicotine, ethanol da cannabinoids a cikin beraye (Espana et al., 2011 ; Mahler et al., 2012 ; Boutrel et al., 2013 ; Flores et al., 2013 ), da kuma cin abinci mai daɗi da yawa da ke da alaƙa da cin abinci mai yawa (Tsujino da Sakurai, 2013 ).
An fara samun bayanai da ke goyon bayan shigar hypocretin/orexin cikin tasirin magungunan jaraba a cikin beraye da ke ɗauke da maye gurbi mara kyau (KO) na hypocretin/orexin peptide, wanda ke nuna alamun raguwar janyewa daga morphine (Georgescu et al., 2003 ). Daga baya, an nuna rashin kyawun wurin da ake so don morphine (Narita et al., 2006 ) da kuma nicotine (Plaza-Zabala et al., 2012 ) a cikin beraye. Kwanan nan, bincike a cikin beraye na KO tare da share mai karɓar OX1 ya nuna raguwar shan cocaine da cannabinoid da kuma toshe hanyar dawo da shan miyagun ƙwayoyi bayan daina shan su (Hollander et al., 2012 ; Flores et al., 2013 ), yana nuna muhimmiyar rawa ga masu karɓar OX1 wajen shiga tsakani wajen dawo da neman miyagun ƙwayoyi.
A cikin beraye SB-334867, wani mai adawa da masu karɓar OX1 da aka fi so, rage yawan hankali, halayyar neman ƙwayoyi da kuma ciwon janyewa a cikin beraye da aka fallasa ga ethanol, nicotine, morphine, da cocaine. An bayyana waɗannan da sauran binciken sosai a cikin sake dubawa na baya-bayan nan (Mahler et al., 2012 ; Boutrel et al., 2013 ). Abin sha'awa musamman shine gaskiyar cewa SB-334867 ya ci gaba da rage halayen tilastawa da ke da alaƙa da dawo da neman ƙwayoyi, wanda ko dai damuwa mai tsanani ko alamun da ke da alaƙa da shan ƙwayoyi suka haifar, wani lamari da aka lura da shi ga ethanol, nicotine, cocaine, cannabinoids da morphine.
Kwanan nan, an gano mai adawa da karɓar OX1 mai zaɓe sosai GSK1059865 (5-bromo-N-[(2S,5S)-1-(3-fluoro-2-methoxybenzoyl)-5-methylpiperidin-2-yl]methyl-pyridin-2-amine) a cikin tarin GSK (Alvaro et al., 2009 ). GSK1059865 a cikin adadin 25 mg/kg ip (wanda aka kiyasta ya mamaye masu karɓar OX1 gaba ɗaya a cikin kwakwalwar bera) ya ɗan canza yanayin barcin beraye kaɗan, yana nuna raunin tasirin hypnotic (Gozzi et al., 2011 ; Piccoli et al., 2012 ) kuma yana tabbatar da bambanci idan aka kwatanta da toshewar masu karɓar OX2 (Mieda et al., 2011 ). Akasin haka, a allurai 10 da 30 mg/kg na ip, GSK1059865 ya yi tasiri sosai kan tasirin cocaine a cikin yanayin fifikon wuri (Gozzi et al., 2011 ). Waɗannan sakamakon sun yi daidai da rawar da aka gabatar na zaɓen mai karɓar OX1 wajen hana komawa ga neman ƙwayoyi amma ba sa haifar da barci.
Masu karɓar OX1 sun kuma shiga cikin tsaka-tsaki a cikin rikice-rikicen cin abinci mai ƙarfi (Avena da Bocarsly, 2012 ), wanda kuma aka ayyana shi a matsayin "jarabar abinci," wani hali na tilastawa da ke ƙara zama ruwan dare a tsakanin mutane masu kiba (Volkow da Wise, 2005 ; Pedram et al., 2013 ). Kodayake da farko an nuna cewa shan orexin-A na tsakiya mai tsanani yana ƙarfafa halayyar ciyarwa ta hanyar yin aiki akan takamaiman da'irorin hypothalamic (Friederich et al., 2013 ), cin abinci mai hypocretin/orexin da hypocretin/orexin ke haifarwa ya bayyana yana da tasiri ga wasu dalilai da yawa, gami da sauƙin abinci, daidaiton kuzari, matakin tashin hankali da yanayin motsin rai (Yamanaka et al., 2003 ; Zheng et al., 2007 ; Choi et al., 2010 ; Tsujino da Sakurai, 2013 ). Wannan yana nuna cewa tsarin hypocretin/orexin zai iya kunna tsarin halaye masu rikitarwa fiye da ƙaruwar abincin da ake ci kawai (Mahler et al., 2012 ). Hakika, binciken da aka yi kwanan nan ya nuna yiwuwar shiga cikin rashin daidaituwar hypocretin/orexin a cikin cin abinci mai daɗi da ake buƙata (Smith da Robbins, 2013 ).
Cin abinci mai ƙarfi ana iya haifar da shi a cikin beraye ta hanyar canza lokutan samun abinci akai-akai tare da lokutan ƙuntata abinci na tsawon makonni kaɗan, wani yanayi na damuwa na yau da kullun wanda zai iya haifar da yawan abinci mai daɗi lokacin da adadin abinci mai daɗi ya fara samuwa kwatsam. An tabbatar da samfurin ta hanyar magunguna a cikin beraye, yana nuna tasirin hana topiramate akan cin abinci mai ƙarfi (Cifani et al., 2009 ) kama da wanda aka lura a cikin masu cin abinci mai ƙarfi na ɗan adam (McElroy et al., 2003 ). Kodayake bayanai game da shigar hypocretin/orexin a cikin wannan hanyar gwaji ta cin abinci mai yawa ba su samuwa ba, mun yi nazarin tasirin GSK1059865 a matsayin kayan aiki don tantance mahimmancin masu karɓar OX1 (Piccoli et al., 2012 ). Abin sha'awa, GSK1059865, a allurai na 10 da 30 mg/kg, bai iya hana cin abinci mai daɗi ga dabbobi masu iko ba (ba a fallasa shi ga ƙuntatawa na abinci mai zagaye ba), yana tabbatar da ƙaramin tasirin toshewar masu karɓar OX1 akan lada na halitta lokacin da ya faru a ƙarƙashin yanayin ilimin halittar jiki. Akasin haka, GSK1059865 ya hana halayyar cin abinci mai ƙarfi a cikin beraye da ke fuskantar damuwa ta yau da kullun/ƙa'idojin abinci (Piccoli et al., 2012 ). Abin sha'awa, cin abinci na yau da kullun an hana shi ta hanyar SB-334867 mai adawa da OX1 a cikin beraye masu saurin kamuwa da kiba amma ba a cikin beraye masu iko ba (White et al., 2005 ). Waɗannan binciken sun tabbatar da rawar da watsawar mai karɓar OX1 ke takawa wajen rage yawan sha'awar da ke tattare da damuwa wanda aka lura da shi tare da magungunan jaraba.
Abin sha'awa, cin abinci mai yawa ya hana shi ta hanyar DORA SB-649868, amma ba ta hanyar mai zaɓaɓɓen mai karɓar OX2 JNJ-10397049 ba, yana nuna cewa tasirin SB-649868 wataƙila ya faru ne saboda ɓangaren OX1 na tsarin aikinsa (Piccoli et al., 2012 ). Abin sha'awa, rashin tasirin almorexant a cikin dabbobin da aka fallasa su ga damuwa mai tsanani ya nuna cewa tsarin canza lokutan ƙuntata abinci yana da mahimmanci don haɗa tsarin hypocretin/orexin wajen haɓaka cin abinci mai daɗi (Funabashi et al., 2009 ; Pankevich et al., 2010 ). Wannan lura ya nuna cewa a cikin wannan yanayin, masu adawa da DORA da OX1 ba sa aiki ta hanyar tasirin hana damuwa. Wannan ba abin mamaki ba ne, idan aka yi la'akari da rawar da hypocretin/orexin ke takawa wajen kula da daidaiton kuzari da kuma yadda jijiyoyin hypocretin/orexin ke amsawa kai tsaye ga canje-canjen matakan glucose da ke yawo da kuma siginar endocrine (Tsujino da Sakurai, 2013 ).
Gabaɗaya, sakamakon da aka samu tare da GSK1059865 ya tabbatar da cewa zaɓaɓɓen ƙiyayya ga masu karɓar OX1 ba ya shafar hanyoyin lada da ke tattare da cin abinci mai daɗi kai tsaye, amma yana goyon bayan rawa a cikin ɓangaren tilasta cin abinci, waɗanda wataƙila ke da alaƙa da ci gaba da dagewar halayen cin abinci marasa kyau a cikin masu cin abinci mai yawa, kuma wataƙila, a cikin marasa lafiya da ke fama da bulimic. Bugu da ƙari, waɗannan bayanan suna nuna buƙatar sake kimanta bayanin ƙiyayya ga masu karɓar OX1, wanda ya dogara da SB-334867 (Haynes et al., 2000 ), wani mahaɗi wanda aka tattauna zaɓinsa a babban adadin da kwanciyar hankali (Hollander et al., 2012 ; McElhinny et al., 2012 ).
Zuwa yanzu, an sami adadi mai yawa na nazarin alamun ɗan adam da ke tallafawa rawar da tsarin hypocretin/orexin ke takawa a cikin rashin daidaituwar halayen da ke nuna jaraba, kuma babu ɗayansu da ya yi amfani da magungunan magunguna. An lura da canje-canje a matakan hypocretin/orexin a cikin jini a cikin masu shan giya yayin daina shan barasa, yana nuna alaƙa mai kyau da alamun damuwa (von der Goltz et al., 2011 ), yayin da aka lura da mummunan alaƙa da alamun sha'awar masu shan taba marasa shan taba (von der Goltze et al., 2010 ). An kuma sami ƙaruwar bayyanar matakan hypocretin/orexin a cikin jinin gefe na masu shan taba sigari da masu shan wiwi (Rotter et al., 2012 ). Duk da cewa fassarar waɗannan binciken har yanzu ba a fayyace ba, an yi nazarin mutanen da abin ya shafa da narcolepsy saboda alhakinsu ga jaraba tare da fatan samun ƙarin sakamako mai ba da labari. Saboda haka, narcolepsy galibi yana da alaƙa da maye gurbi a cikin kwayar halittar hypocretin/orexin (Peyron et al., 1998 ), wanda ke haifar da ƙarancin peptide, kama da wanda aka samu a cikin beraye na hypocretin/orexin KO. An ruwaito bambance-bambance masu sauƙi a cikin sarrafa lada da halayen ɗaukar haɗari a cikin waɗanda ke fama da narcoleptic, amma yawan shan taba a cikin waɗannan marasa lafiya bai bambanta da na al'ada ba (Bayard da Dauvilliers, 2013 ). Akwai sakamako daban-daban tare da shaidar raguwar tasirin magungunan jaraba a cikin beraye na hypocretin/orexin KO (don bita duba Mahler et al., 2012 ; Boutrel et al., 2013 ). Abin sha'awa, waɗanda ke fama da narcolepsy sun ayyana amfani da shan taba sigari da facin nicotine a matsayin magani na kansu don rage barci da ƙara tashin hankali (Ebben da Krieger, 2012 ). Gabaɗaya, binciken ya nuna sarkakiya a cikin dangantakar da ke tsakanin halayen jaraba da tsarin hypocretin/orexin mara aiki a cikin mutane, yana tallafawa buƙatar ƙarin nazarin fassara mai zurfi.
Munafukai / jinsin da kuma OX1 mai karɓa a cikin damuwa
Littattafan ilimin halittar jiki sun bayyana yankunan baya da na gefe na hypothalamus a matsayin wani ɓangare na da'irar limbic wanda ke sarrafa halayen "yaƙi ko gudu" don mayar da martani ga barazanar da ke gabatowa (Hess da Akert, 1955 ). Kamar yadda aka ambata a sama, ƙwayoyin jijiyoyi waɗanda ke samar da hypocretin/oirexin suna cikin yankin perifornical (Peyron et al., 1998 ) kuma suna yin nuni ga yawancin tsarin kwakwalwar limbic da ke da hannu a cikin da'irar tsoro, damuwa da damuwa (Shin da Liberzon, 2009 ), suna nuna yiwuwar rawar da hypocretin/orexin ke takawa wajen sarrafa ba kawai farkawa da tashin hankali ba, har ma da martanin tsoro, damuwa, da damuwa (Johnson et al., 2012a ; Sears et al., 2013 ).
An bincika wannan hasashe tsawon shekaru kuma an taƙaita shi a cikin labarai da sake dubawa na baya-bayan nan (Bisetti et al., 2006 ; Mathew et al., 2008 ; Johnson et al., 2010 , 2012a ). A cikin waɗannan gudummawar, masu karatu masu sha'awar za su iya samun shaidar da ke goyon bayan rawar da jijiyoyin hypocretin/orexin ke takawa wajen tsara martanin kai tsaye, na numfashi, na zuciya da jijiyoyin jini ga abubuwan da ke haifar da damuwa da firgici.
Halin aiki yana nuna cewa matsalolin danniya (ko matsanancin matsayi na masu gwagwarmayar tashin hankali) zai ƙara aiki a kan hypocretin / orexin neurons, wanda hakan zai ba da karin hypocretin / orexin a cikin filayen filayen da ke cikin ƙananan yankunan kwakwalwa wanda ke tsara motsin rai da amsa matakan. . Sa'an nan kuma hypocretin / orexin zai canja matakin matakin kunnawa na tsoro, damuwa da damuwa kewaye zuwa matakin mafi girma na arousal, wanda ya hada da vegetative, endocrin da kuma halin kwaikwayo na hali irin na damuwa da damuwa jihohi. Ana iya ganin mummunan ci gaba da tsauraran munafurci da ƙaranci a matsayin muhimmiyar mahimmanci wajen tabbatar da jin dadi da damuwa, kazalika da alhakin sake dawowa cikin abubuwan tsoro a cikin mutanen da suka rigaya sunyi tunanin, suna nuna yiwuwar matsanancin matsayi na damuwa ga damuwa.
Bayanai a cikin mutane sun nuna ƙaruwar sakin hypocretin/orexin daga cikin ƙwayoyin halitta wanda motsin rai ke haifarwa a cikin amygdala na mutanen da ke fama da farfaɗiyar lobe mai jure magani wanda aka dasa tare da binciken microdialysis (Blouin et al., 2013 ). A cikin wannan binciken, matakan hypocretin/orexin sun ƙaru yayin farkawa kuma sun ragu yayin barci, amma an lura da mafi girman kololuwa yayin kunna motsin rai mai tsanani na valence mai kyau da mara kyau. Ana ɗaukar amygdala a matsayin babban tsari don sarrafa motsin rai mai daɗi da mara kyau, wanda ke da alaƙa da damuwa ta cuta. A cikin beraye, allurar hypocretin/orexin a cikin amygdala yana ƙara halayyar kamar damuwa (Avolio et al., 2011 ). Abin sha'awa, an sami matakan hypocretin/orexin marasa kyau a cikin ruwan cerebro-spinal (CSF) na marasa lafiya da ke fama da Rashin Damuwa na Panic, yana nuna yiwuwar yanayin aiki mai yawa (Johnson et al., 2010 ). A wani bincike kuma, an auna ƙaruwar matakan hypocretin/orexin a cikin jinin gefe na mutanen da ke fama da cutar toshewar huhu ta yau da kullun (COPD), yanayin da ke da alaƙa da hypercapnia, acidosis da kuma ƙaruwar haɗarin hare-haren firgici sau 10 (Zhu et al., 2011 ).
Sakamakon binciken yana nuna cewa kayan halayen na hypocretin / orexin sunyi mahimmanci ne ta hanyar haɗin masu karɓa na OX1. A cikin rodents da maganganun da suka dace da kuma halin da ake ciki ga danniya sun rage ta hanyar maganin magunguna tare da masu karɓar sakonta na OX1, irin su SB-334867 (Johnson et al., 2010, 2012b), GSK 1034865 (Gozzi et al., 2011) da kuma ACT-335827 (Steiner et al., 2013), ko tare da DORA, irin su almorexant (Steiner et al., 2012). An lura da mahimmanci mai mahimmanci irin wadannan maganganu a cikin yanayin da suka hada da yanayin jin tsoro (Sears et al., 2013; Steiner et al., 2013), jigilar lactate panicogenic (Johnson et al., 2010), hypercapnia (Li et al., 2010; Johnson et al., 2012b), gwamnatin FG-7142 (Johnson et al., 2012a), babban nau'in nicotine (Plaza-Zabala et al., 2010), da kuma yohimbine (Richards et al., 2008). Bayanan da aka yi amfani da ita ta amfani da OX1 da OX2 KO mice sun nuna tasiri mai mahimmanci na masu karɓar OX1 da ke cikin coeruleus a cikin kafofin watsa labaran da suka shafi kwarewa da kwarewa da kuma ƙaddamarwar ƙwaƙwalwa (Sears et al., 2013; Soya et al., 2013).
Shaidar da ke nuna cewa ƙwayoyin jijiyoyi masu ɗauke da hypocretin/orexin suna karɓar bayanai daga wasu ƙwayoyin jijiyoyi waɗanda ke samar da sinadarin peptide corticotropin mai sakin peptide (CRF) na anxiogenic kuma cewa ƙwayoyin jijiyoyi masu ɗauke da hypocretin/orexin suna aiki zuwa yankunan kwakwalwa masu arzikin CRF sun nuna yiwuwar waɗannan tsarin peptidergic guda biyu suna aiki a cikin sarrafa amsawar damuwa (Ida et al., 2000 ; Pañeda et al., 2005 ). Duk da haka, idan wannan hasashe ya yi daidai, halayen anxiolytic na masu adawa da CRF-1 (Zorrilla da Koob, 2004 ) da na masu adawa da OX1 za su haɗu, suna nuna irin waɗannan bayanan martaba. Abin sha'awa, wani bincike da aka yi kwanan nan ta amfani da phMRI a cikin beraye ya nuna cewa shigar CRF-1 da OX1 cikin martanin damuwa za a iya raba su ta hanyar aiki. A cikin wannan gwajin an samo taswirar kwakwalwa ta kunna phMRI a cikin beraye tare da yohimbine a allurai da aka sani suna haifar da tasirin anxiogenic. An yi jiyya kafin a fara amfani da CP-154,526, wani mai adawa da CRF-1 mai zaɓe (Seymour et al., 2003 ), ko kuma mai adawa da mai karɓar OX1 mai zaɓe GSK1059865 (Gozzi et al., 2011 ). Taswirar kwakwalwar kunnawar yohimbine ta rage ta hanyar CP-154,526 a cikin injin, cingulate, retrosplenial, dorsal prefrontal cortex, sassan dorsal na caudate-putamen, da kuma a cikin amygdala. Sabanin haka, GSK1059865 ya rage taswirar kunnawar yohimbine a cikin nucleus accumbens, septum, dorsal thalamus, amygdala, ventral hippocampus, orbitofrontal, prefrontal, insular, cingulate retrosplenial, da piriform cortex (Gozzi et al., 2013 ). Gabaɗaya, mai adawa da mai karɓar OX1 ya yi tasiri mai yawa akan da'irar tsoro, damuwa da damuwa fiye da mai adawa da CRF1, yana rage ayyukan yankuna na tsarin dopaminergic mesolimbic. Dangane da abin da aka lura a baya, an gano rabuwar kai tsakanin tasirin masu adawa da OX1 da CRF-1 akan tsarin dopamine na bera a cikin cocaine mai haifar da damuwa (Wang et al., 2009 ) da neman nicotine (Plaza-Zabala et al., 2012 ).
Abin sha'awa, a wasu bincike, duka masu adawa da OX1 da DORAs ba su nuna tasirin damuwa a cikin gwaje-gwajen halaye na musamman ba (misali, maze mai girma da ƙari) (Steiner et al., 2012 ; Rodgers et al., 2013 ). Waɗannan bayanan sun yi daidai da hasashen cewa masu adawa da masu karɓar hypocretin/orexin ba sa canza matakan damuwa na asali a cikin beraye, amma suna nuna halayen anxiolytic lokacin da matakan damuwa suka tsananta na ɗan lokaci ta hanyar abubuwan da ke haifar da ƙarfi kamar acidosis/hypercapnia.
Ƙuntatawa da ƙarshe
An sake duba dalilin la'akari da masu karɓar OX1 a matsayin waɗanda za a iya cimmawa a cikin yanayi kamar Matsalolin Damuwa, Shan Miyagun Kwayoyi, da Cin Abinci Mai Tsanani. Dangane da ilimin da ake da shi a yanzu game da tsarin aiki, masu adawa da masu karɓar OX1 ya kamata su sami ƙarancin haɗarin ci gaba fiye da DORAs. Kamar yadda Scammell da Winrow ( 2011 ) da Boutrel et al. ( 2013 ) suka nuna ga DORAs, toshewar masu karɓar hypocretin/orexin na lokaci guda na iya iya: (1) haifar da alamun kamar narcoleptic, gami da catalepsy; (2) lalata yanke shawara mai ma'ana; (3) rage jin daɗi da ke tattare da ayyukan lada; (4) haifar da nutsuwa, barci da kuma rashin amsawar da ta dace a ƙarƙashin gaggawa ko damuwa mai tsanani; (5) tasiri akan metabolism na asali tare da ƙaruwar nauyin jiki. Duk da haka, zuwa yanzu, ƙwarewar ɗan adam tare da DORAs suvorexant, SB-649868 da almorexant abin ƙarfafa gwiwa ne, yana nuna ƙarancin faruwar abubuwan da suka faru a sama, musamman ma, babu haifar da narcoleptic eoisodes ko raunin aikin yanke shawara lokacin da aka gwada su a cikin kewayon maganin da aka gabatar a halin yanzu. Duk da haka, ana buƙatar ƙarin bayanai kan yawan jama'a da kuma yawan allurai don cimma ƙarshe.
Abin sha'awa, ba a tsammanin jiyya tare da masu adawa da OX1 da aka zaɓa za su raba irin wannan haɗarin na DORAs ba tunda mai karɓar OX2 kawai yana da alaƙa da narcolepsy wanda aka nuna ga karnuka waɗanda ke ɗauke da maye gurbin kwayoyin halitta mai rikitarwa na wannan mai karɓar (Wu et al., 2011 ). Ƙarin fa'idodin mai adawa da OX1 sun haɗa da: (1) Bayanin anxiolytic na farko wanda ya bambanta shi da benzodiazepines, masu hana serotonin-uptake, da masu adawa da CRF-1; (2) Ikon rage yanayin tashin hankali mai yawa da ke da alaƙa da yanayin tashin hankali mai tsanani da tsanani tare da alamun jiki masu dacewa, kamar hare-haren tsoro ko janyewa daga magungunan jaraba; (3) Rage halayen tilastawa da maimaitawa da ke da alaƙa da hankali, rage damuwa, ko neman magani; (4) Rashin tasirin da ke kan sha'awar lada ta halitta, da (5) rashin tasirin da ke haifar da barci.
Wadannan ƙididdiga sun dogara ne akan ƙayyadaddun ƙididdiga na ƙididdigar ƙididdiga, amma kwanan nan an gudanar da su tare da sababbin ƙwararrun masu zaɓaɓɓe. Bayanan nazarin nazarin binciken ya ɓace kuma sabili da haka ba a samo asali game da hadarin lokaci da wadata ba tukuna. Bugu da ƙari, ba a taɓa gwada masu gwagwarmaya ta OX1 mai karɓa ba a gwaji a cikin mutane har ya zuwa yau kuma damun fassara ba shi da tabbacin. Duk da haka, alamar kyakkyawan sakamako a cikin tasirin nauyin halayya da kuma tilasta halayen yana ƙarfafa ƙarin bincike na musamman kuma yana ƙarfafa ayyukan zuba jari na kamfanoni.
Rikici na sanarwa mai amfani
Emilio Merlo Pich shine ma'aikaci na F. Hoffman-La Roche. Wani mawallafin ya furta cewa binciken ya gudanar ne idan ba a samu wata kasuwanci ko kudi ba wanda za a iya ɗauka a matsayin wani rikici na sha'awa.
References
- Alvaro G., Amantini D., Stasi L. (2009). Abun dajin da aka yi amfani da shi na Pyridine da ake amfani dashi don magance matsalar Orexin. WO 2009124956. PCT Int. Appl.
- Avena NM, Bocarsly ME (2012). Dysregulation na kwakwalwa ladabi tsarin a yanayin cin abinci: bayanai neurochemical daga dabbobin dabba na cin abinci cin abinci, bulimia nervosa, da kuma anorexia nervosa. Neuropharmacology 63, 87-96 10.1016 / j.neuropharm.2011.11.010 [PMC free article] [PubMed] [Cross Ref]
- Avolio E., R. R., Carelli A., Canonaco M. (2011). Ayyukan amfanar Amygdalar-GABAergic ne ke tsara yanayin tashin hankali na hamster na Siriya. Behav. Brain Res. 218, 288-295 10.1016 / j.bbr.2010.11.014 [PubMed] [Cross Ref]
- Bayard S., Dauvilliers YA (2013). Ayyukan sakamako na sakamako da aiki tare a cikin mutum tare da narcolepsy-cataplexy. Gabar. Behav. Neurosci. 7: 50 10.3389 / fnbeh.2013.00050 [PMC free article] [PubMed] [Cross Ref]
- Bettica P., Squassante L., Zamuner S., Nucci G., Danker-Hopfe D., Ratti E. (2012). Sanda-shen-Sn-649868 wanda ke tayar da hankali yana inganta da kuma kula da barci a cikin maza da rashin barci na farko. 35 barci, 1097-1104 10.5665 / barci.1996 [PMC free article] [PubMed] [Cross Ref]
- Bisetti A., Cvetkovic V., Serafin M., Bayer L., Machard D., Jones BE, et al. (2006). Ayyuka na yaudarar hypocretin / mintina a kan takalma na tsakiyar amygdala tsakiyar. Neuroscience 142, 999-1004 10.1016 / j.neuroscience.2006.07.018 [PubMed] [Cross Ref]
- Blouin AM, Fried I., Wilson CL, Staba RJ, Behnke EJ, Lam HA, et al. (2013). Mutum munafurci da mibanin-mayar da hankali ga matakan hormone an danganta su da halayyar tausayi da zamantakewa. Nat. Sadarwa. 4, 1547-1553 10.1038 / ncomms2461 [PMC free article] [PubMed] [Cross Ref]
- Boutrel B., Steiner N., Halfon O. (2013). Munafukai da aikin sakamako: menene muka koya har yanzu? Gabar. Behav. Neurosci. 7: 59 10.3389 / fnbeh.2013.00059 [PMC free article] [PubMed] [Cross Ref]
- Choi DL, Davis JF, Fitzgerald ME, Benoit SC (2010). Matsayin da ke da kyau a cikin abincin abinci, cin abinci da cin abinci da cin abinci da kuma abin da aka samar da abinci ne a cikin ratsi. Neuroscience 167, 11-20 10.1016 / j.neuroscience.2010.02.002 [PubMed] [Cross Ref]
- Cifani C., Polidori C., Melotto S., Ciccocioppo R., Massi M. (2009). Kyakkyawan samfurin cin abinci mai cin nama da ake ciki da yo-yo dieting da damuwa ga abincin: sakamako na sibutramine, fluoxetine, topiramate, da midazolam. Psychopharmacology (Berl.) 204, 113-125 10.1007 / s00213-008-1442-y [PubMed] [Cross Ref]
- de Lecea L., Kilduff TS, Peyron C., Gao XB, Foye PE, Danielson PE, et al. (1998). The hypocretins: peptides musamman-peptides tare da neuroexcitatory aiki. Shaida. Natl. Acad. Sci. Amurka 95, 322-327 10.1073 / pnas.95.1.322 [PMC free article] [PubMed] [Cross Ref]
- Ebben MR, Krieger AC (2012). Narcolepsy da cataplexy masked ta amfani da nicotine. J. Clin. Madaurar Magana. 8, 195-196 10.5664 / jcsm.1780 [PMC free article] [PubMed] [Cross Ref]
- Ekholm ME, Johannson L., Kukkonen JP (2007). IP3 alamar kai tsaye na OX1 orexin / hypocretin receptor zuwa Ca2 + tasiri da ERK. Biochem. Biofys. Res. Sadarwa. 353, 475-480 10.1016 / j.bbrc.2006.12.045 [PubMed] [Cross Ref]
- Espana RA, Melchior JR, Roberts DC, Jones SR (2011). Maganin 1 / orexin A a cikin yanki na kwakwalwa ya inganta karfin maganin maganin maganin maganin cocaine kuma yana inganta gine-ginen ciwon cocaine. Psychopharmacology (Berl.) 214, 415-426 10.1007 / s00213-010-2048-8 [PMC free article] [PubMed] [Cross Ref]
- Faedo S., Perdonà E., Antolini M., da Fabio R., Merlo Pich E., Corsi M. (2012). Ayyukan aiki da kuma ɗaukar nauyin haɓaka suna nuna bambanci tsakanin OX 1 da OX2 orexin receptor antagonists. Eur. J. Pharmacol. 692, 1-9 10.1016 / j.ejphar.2012.07.007 [PubMed] [Cross Ref]
- Flores A., Maldonado R., Berrendero F. (2013). Mai karɓar littattafan hypocretin / mai sauƙi-1 a matsayin wani sabon labari wanda zai iya canza cannabinoid sakamako. Biol. 3223 masu ilimin zuciya, 590-598 10.1016 / j.biopsych.2013.06.012 [PubMed] [Cross Ref]
- Friederich HC, Wu M., Simon JJ, Herzog W. (2013). Neurocircuit aiki a cikin cin abinci. Int. J. Ku ci. Disord. 46, 425-432 10.1002 / eat.22099 [PubMed] [Cross Ref]
- Funabashi T., Hagiwara H., Mogi K., Mitsushima D., Shinohara K., Kimura F. (2009). Bambancin jima'i a cikin martani na ƙananan igiya a cikin yankin hypothalamic na gefe da kuma ciyar da hali zuwa azumi. Neurosci. Lett. 463, 31-34 10.1016 / j.neulet.2009.07.035 [PubMed] [Cross Ref]
- Gatfield J., Brisbare-Roch C., Jenck F., Boss C. (2010). Magunguna masu karɓar mai karfin Orexin: wani sabon ra'ayi a cikin sassan CNS? ChemMedChem 5, 1197-1214 10.1002 / cmdc.201000132 [PubMed] [Cross Ref]
- Georgescu D., Zachariou V., Barrot M., Mieda M., Willie JT, Eisch AJ (2003). Yin amfani da peptide orexin a cikin kwaskwarima a cikin ƙarancin morphine da kuma sauƙi. J. Neurosci. 23, 3106-3111 10.1002 / micr.10128 [PubMed] [Cross Ref]
- Gotter AL, Roecker AJ, Hargreaves R., Coleman PJ, Winrow CJ, Renger JJ (2012). Magungunan Orexin a matsayin maganin miyagun kwayoyi. Prog. Brain Res. 198, 163-188 10.1016 / B978-0-444-59489-1.00010-0 [PubMed] [Cross Ref]
- Gozzi A., Lepore S., Vicentini E., Merlo-Pich E., Bifone A. (2013). Sakamakon bambancin sakamako na Xiaoxin-1 da CRF-1 a kan wasu matakan damuwa: binciken fMRI a cikin bera tare da magungunan pharmacological stress yohimbine. Neuropsychopharmacology 38, 2120-2130 10.1038 / npp.2013.109 [PMC free article] [PubMed] [Cross Ref]
- Gozzi A., Turrini G., Piccoli L., Massagrande M., Amantini D., Antolini M., et al. (2011). Hanyoyin haɓakaccen haɓakaccen aikin haɓaka suna nuna nau'o'in ƙananan ƙananan hanyoyi don abubuwan da ke tattare da magunguna-1 da masu haɓaka mai karɓar nau'in mai sauƙi-2. KASHE KASAN 6: e16406 10.1371 / journal.pone.0016406 [PMC free article] [PubMed] [Cross Ref]
- Harris GC, Wimmer M., Aston-Jones G. (2005). Matsayi ga takaddama masu tsinkaye na hypothalamic a cikin ladabi. Yanayin 437, 556-559 10.1038 / nature04071 [PubMed] [Cross Ref]
- Haynes AC, Jackson B., Chapman H., Tadayyon M., Johns A., Porter RA, et al. (2000). Mai karɓar mai karɓa mai sauƙi na Xiaoxin-1 ya rage rage cin abinci a cikin ratsan mata da na mace. Regul. Pept. 96, 45-51 10.1016 / S0167-0115 (00) 00199-3 [PubMed] [Cross Ref]
- Heinonen MV, Purhonon AK, Makela KA, Herzig KH (2008). Ayyuka na sauxin a cikin jiki na jiki. Acta Physiol. (Oxf.) 192, 471-485 10.1111 / j.1748-1716.2008.01836.x [PubMed] [Cross Ref]
- Gwaninta WJ, Snyder E., Budd K., Hutzelmann J., Snavely D., Liu K., et al. (2012). Antagonism mai karɓar maganin Orexin don maganin rashin barci: wani gwaji na asibiti na suvorexant. Nano 79, 2265-2274 10.1212 / WNL.0b013e31827688ee [PubMed] [Cross Ref]
- Hess WR, Akert K. (1955). Bayanai na gwaji akan tasirin hypothalamus a cikin tsari na halin halayyar. AmA Arch. Neurol. 73 masu ilimin zuciya, 127-129 10.1001 / archneurpsyc.1955.02330080005003 [PubMed] [Cross Ref]
- Hoever P., Dorffner G., Bene H., Penzel T., Danker-Hopfe H., Barbanoj MJ, et al. (2012). Antagonism mai karɓar rawanin Orexin, sabon yanayin barci: jarrabawar gwaji ta gwaji. Clin. Pharmacol. Ther. 91, 975-985 10.1038 / clpt.2011.370 [PMC free article] [PubMed] [Cross Ref]
- Hollander JA, Pham D., Fowler CD, Kenny PJ (2012). Masu sauraron munafurci-1 suna tsara nauyin haɓakawa da kuma sakamako masu haɓakawa na hawan cocaine: shaidar maganin maganin maganin magunguna da halayyar mutum. Gabar. Behav. Neurosci. 6: 47 10.3389 / fnbeh.2012.00047 [PMC free article] [PubMed] [Cross Ref]
- Ida T., Nakahara K., Murakami T., Hanada R., Nakazato M., Murakami N. (2000). Mai yiwuwa yiwuwar sanya hannu a cikin danniya danniya a cikin berayen. Biochem. Biofys. Res. Sadarwa. 270, 318-323 10.1006 / bbrc.2000.2412 [PubMed] [Cross Ref]
- Jiang R., Song X., Bali P., Smith A., Bayona CR, Lin L., et al. (2012). Turaridin da ba'a dasu ba ne kamar yadda masu karɓar rashawa na talikanci (hypocretin) suka yi. Bioorg. Mad. Chem. Lett. 12, 3890-3894 10.1016 / j.bmcl.2012.04.122 [PMC free article] [PubMed] [Cross Ref]
- Johnson PL, Molosh A., Fitz SD, Truitt WA, Shekhar A. (2012a). Orexin, damuwa, da damuwa / jin tsoro. Prog. Brain Res. 198, 133-161 10.1016 / B978-0-444-59489-1.00009-4 [PMC free article] [PubMed] [Cross Ref]
- Johnson PL, Samuels BC, Fitz SD, Federici LM, Hammes N., Early MC, et al. (2012b). Masu karɓar nauyin 1 na Orexin su ne mahimmanci ne don sauya martani game da martani da kuma kwakwalwar kwakwalwa. Physiol. Behav. 107, 733-742 10.1016 / j.physbeh.2012.04.016 [PMC free article] [PubMed] [Cross Ref]
- Johnson PL, Truitt W., Fitz SD, Pear Minick, Dietrich A., Sanghani S., et al. (2010). Babban mahimmanci ga orexin a cikin tsoro tsoro. Nat. Mad. 16, 111-115 10.1038 / nm.2075 [PMC free article] [PubMed] [Cross Ref]
- Jones DNC, Gartlon J., Parker F., Taylor SG, Routledge C., Hemmati P., et al. (2001). Hanyoyin da ake amfani da su a cikin bita-B da orexin-A: rawar da masu karɓar nauyin na Xiaoxin-1 suke a cikin hyperactivity a cikin ƙarancin sauƙi. Psychopharmacology 153, 210-218 10.1007 / s002130000551 [PubMed] [Cross Ref]
- Lebold TP, Bonaventure P., Shireman BT (2013). Mai karɓaccen mai karɓa mai karɓa mai sauƙi. Bioorg. Mad. Chem. Lett. 223, 4761-4769 10.1016 / j.bmcl.2013.06.057 [PubMed] [Cross Ref]
- Li Y., Li S., Wei C., Wang H., Sui N., Kirouac GJ (2010). Orexin a cikin tsakiya mai banƙyama na thalamus na jaddada tashin hankali-kamar amsa a cikin berayen. Dychopharmacology 212, 251-265 10.1007 / s00213-010-1948-y [PubMed] [Cross Ref]
- Lund PE, Sakarimari R., Uustare A., Detheux M., Parmentier M., Kukkonen JP (2000). Mai karɓa na OX1 mai sauƙi yana taimakawa hanyar hanyar haruffa ta hanyar CX Biol. Chem. 2, 275-30806 30812 / jbc.M10.1074 [PubMed] [Cross Ref]
- Mahler SV, Smith RJ, Moorman DE, Sartor GC, Aston-Jones G. (2012). Matsayi mai yawa don orexin / hypocretin a cikin buri. Prog. Brain Res. 198, 79-121 10.1016 / B978-0-444-59489-1.00007-0 [PMC free article] [PubMed] [Cross Ref]
- Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M., et al. (2001). Maganin bambanci na masu karɓar nauyin ninkin 1 da 2 a cikin kwakwalwan kwari. J. Comp. Neurol. 435, 6-25 10.1002 / cne.1190 [PubMed] [Cross Ref]
- Matsaw SJ, Farashin RB, Charney DS (2008). Nasarar kwanan nan a cikin kwayar halitta na rashin tausayi: abubuwan da ke faruwa ga magunguna. Am. J. Med. Genet. C Semin. Mad. Genet. 148C, 89-98 10.1002 / ajmg.c.30172 [PubMed] [Cross Ref]
- McElhinny CJ, Jr., Lewin AH, Mascarella SW, Runyon S., Brieaddy L., Carroll FI (2012). Rashin rashin lafiya na ruwa mai mahimmanci mai karɓa na 1 mai karɓar SB-334867: yiwuwar rikicewa a kan a vivo da kuma a vitro nazarin. Bioorg. Mad. Chem. Lett. 22, 6661-6664 10.1016 / j.bmcl.2012.08.109 [PubMed] [Cross Ref]
- McElroy SL, Arnold LM, Shapira NA, Keck PE, Jr., Rosenthal NR, Karim MR, et al. (2003). Topiramate a lura da ciwon ciwon binge da ke hade da kiba: gwajin gwagwarmaya, inda ake sarrafawa. Am. J. Neman 160, 255-261 10.1176 / appi.ajp.160.2.255 [PubMed] [Cross Ref]
- Mieda M., Hasegawa E., Kisanuki YY, Sinton CM, Yanagisawa M., Sakurai T. (2011). Matsayi daban-daban na mai karɓa mai sauƙi-1 da -2 a cikin tsari na wadanda ba REM da REM barci ba. J. Neurosci. 31, 6518-6526 10.1523 / JNEUROSCI.6506-10.2011 [PMC free article] [PubMed] [Cross Ref]
- Narita M., Nagumo Y., Hashimoto S., Khotib J., Miyatake M., Sakurai T. (2006). Hanyar kai tsaye ga tsarin tsarin kayan aiki a cikin kunna hanyar hanyar kwayoyin mesolimbic da kuma sauran halayen da morphine suka haifar. J. Neurosci. 26, 398-405 10.1523 / JNEUROSCI.2761-05.2006 [PubMed] [Cross Ref]
- Pañeda C., Winsky-Sommerer R., Boutrel B., de Lecea L. (2005). Corticotropin-sakewa factor-hypocretin haɗin kai: abubuwan a cikin matukar amsa da damuwa. Drug News Perspect. 18, 250-255 10.1358 / dnp.2005.18.4.908659 [PubMed] [Cross Ref]
- Pankevich DE, Teegarden SL, Hedin AD, Jensen CL, Bale TL (2010). Harkokin caloric ƙwarewa yana haifar da damuwa da hanyoyi masu dacewa kuma yana inganta binge cin abinci. J. Neurosci. 30, 16399-16407 10.1523 / JNEUROSCI.1955-10.2010 [PMC free article] [PubMed] [Cross Ref]
- Pedram P., Wanda D., Amini P., Gulliver W., Randell E., Cahill F., et al. (2013). Abincin da ake amfani da abinci: ƙaddararsa da muhimmiyar dangantaka da kiba cikin yawan jama'a. KASHE KASAN 8: e74832 10.1371 / journal.pone.0074832 [PMC free article] [PubMed] [Cross Ref]
- Peyron C., Tighe DK, van den Pol AN, de Lecea L., Heller HC, Sutcliffe JG, et al. (1998). Neurons dauke da hypocretin (orexin) aikin zuwa tsarin da yawa neuronal. J. Neurosci. 18, 9996-10015 [PubMed]
- Piccoli L., Micioni Di Bonaventura MV, Cifani C., Costantini VJ, Massagrande M., Montanari D., et al. (2012). Sakamakon ayyukan mai karɓar nauyin ninkin-1 a kan cin abinci mai karfi a cikin samfurin binge ci a cikin ratsan mata. Neuropsychopharmacology 37, 1999-2011 10.1038 / npp.2012.48 [PMC free article] [PubMed] [Cross Ref]
- Plaza-Zabala A., Flores A., Maldonado R., Berrendero F. (2012). Alamar munafurci / Orexin a cikin magungunan kwakwalwa na hypothalamic yana da mahimmanci don nuna rashin jan hankalin nicotine. Biol. 71 masu ilimin zuciya, 214-223 10.1016 / j.biopsych.2011.06.025 [PubMed] [Cross Ref]
- Plaza-Zabala A., Martín-García E., de Lecea L., Maldonado R., Berrendero F. (2010). Munafukai suna tsara nauyin nau'in nicotine kamar nau'i-nau'i-nau'i da kuma haifar da sake dawowa da halayen nicotine. J. Neurosci. 30, 2300-2310 10.1523 / JNEUROSCI.5724-09.2010 [PMC free article] [PubMed] [Cross Ref]
- Richards JK, Simms JA, Steensland P., Taha SA, Borgland SL, Bonci A., et al. (2008). Rashin hana masu karɓar nauyin na Xaxin-1 / hypocretin-1 ya haifar da sake dawowa da yaduwar yadubin da yarinya da kuma neman yarinya a cikin ratsan tsinkaye. Psychopharmacology (Berl.) 199, 109-117 10.1007 / s00213-008-1136-5 [PMC free article] [PubMed] [Cross Ref]
- Rodgers RJ, Wright FL, Snow NF, Taylor LJ (2013). Antagonism mai karɓar nauyin Orexin-1 ya kasa rage halin da ke cikin damuwa a cikin ƙwayoyin maɗaukaki-maze-naïve ko ma-daze-mice. Behav. Brain Res. 243, 213-219 10.1016 / j.bbr.2012.12.064 [PubMed] [Cross Ref]
- Rotter A., Bayerlein K., Hansbauer M., Weiland J., Sperling W., Kornhuber J., et al. (2012). Orexin A nunawa da mai gabatarwa methylation a marasa lafiya tare da cannabis dogara ne a kwatanta da masu shan taba taba masu dogara da nicotine da masu ƙyama. Neuropsychobiology 66, 126-133 10.1159 / 000339457 [PubMed] [Cross Ref]
- Sakura T., Amemiya A., Ishii M., Matsuzaki I., Chemelli RM, Tanaka H., et al. (1998). Orexins da kuma masu karɓar mahaifa: iyalin neuropeptides hypothalamic da kuma masu haɗin g sunadarai na G wanda ke tsara tsarin cin abinci. Cell 92, 573-585 10.1016 / S0092-8674 (00) 80949-6 [PubMed] [Cross Ref]
- Tambaya TE, Winchester CJ (2011). Sauran masu karɓar Orexin: ilimin likita da kuma ilmin likita. Annu. Rev. Pharmacol. Toxicol. 51, 243-266 10.1146 / annurev-pharmtox-010510-100528 [PMC free article] [PubMed] [Cross Ref]
- Sears RM, Fink AE, Wigestrand MB, Farb CR, de Lecea L., Ledoux JE (2013). Harshen Orexin / hypocretin yana canza yanayin barazanar amygdala-dogara ta hanyar coeruleus. Shaida. Natl. Acad. Sci. Amurka 110, 20260-20265 10.1073 / pnas.1320325110 [PMC free article] [PubMed] [Cross Ref]
- Seymour PA, Schmidt AW, Schulz DW (2003). Kayan magani na CP-154,526, mai tayar da kullin peptide na mai karɓar CRH1: bita. Rikicin Drug na CNS 9, 57-96 10.1111 / j.1527-3458.2003.tb00244.x [PubMed] [Cross Ref]
- Shin LM, Liberzon I. (2009). Neurocircuitry na tsoro, damuwa, da kuma tashin hankali cuta. Neuropsychopharmacology 35, 169-191 10.1038 / npp.2009.83 [PMC free article] [PubMed] [Cross Ref]
- Smart D., Sabido-David C., Brough SJ, Jewitt F., Johns A., Porter RA, et al. (2001). SB-334867-A: na farko wanda zaɓaɓɓen mai karɓa mai sauƙi na Xiaoxin-1. Br. J. Pharmacol. 132, 1179-1182 10.1038 / sj.bjp.0703953 [PMC free article] [PubMed] [Cross Ref]
- Smith DG, Robbins TW (2013). Tsarin kwayoyin halitta na kiba da kuma cin nama: abin da ya dace domin ƙaddamar da ƙwayar abinci. Biol. 73 masu ilimin zuciya, 804-810 10.1016 / j.biopsych.2012.08.026 [PubMed] [Cross Ref]
- Soya S., Shoji H., Hasegawa E., Hondo M., Miyakawa T., Yanagisawa M., et al. (2013). Mai karɓa na Orexin-1 a cikin coeruleus yankin yana taka muhimmiyar rawa wajen farfadowa da ƙwaƙwalwar ajiyar ƙwaƙwalwa. J. Neurosci. 33, 14549-14557 10.1523 / JNEUROSCI.1130-13.2013 [PubMed] [Cross Ref]
- Steiner MA, Gatfield J., Brisbare-Roch C., Dietrich H., Treiber A., Jenck F., et al. (2013). Binciken da kuma halayyar ACT-335827, a bayyane yake, kwakwalwa mai karɓar nau'in mai amfani typeNNUMX mai zafin jiki. ChemMedChem 1, 8-898 903 / cmdc.10.1002 [PubMed] [Cross Ref]
- Steiner MA, Lecourt H., Jenck F. (2012). Kwayar tsarin kwakwalwa da kuma maɗaukaki a cikin mummunan halayen da ake ciki a cikin bera. Psychopharmacology (Berl.) 223, 465-475 10.1007 / s00213-012-2736-7 [PubMed] [Cross Ref]
- Tsujino N., Sakurai T. (2013). Matsayi na nishaɗi a cikin gyaran ƙanshi, ciyarwa, da kuma dalili. Gabar. Behav. Neurosci. 7: 28 10.3389 / fnbeh.2013.00028 [PMC free article] [PubMed] [Cross Ref]
- Volkow ND, Hikimar RA (2005). Ta yaya likita miyagun ƙwayoyi zai taimake mu mu fahimci kiba? Nat. Neurosci. 8, 555-560 10.1038 / nn1452 [PubMed] [Cross Ref]
- von der Goltz C., Koopmann A., Dinter C., Richter A., Grosshans M., Fink T., et al. (2011). Yin amfani da samfurori a cikin tsari na damuwa, damuwa da lada a cikin maye gurbi. Horm. Behav. 60, 644-650 10.1016 / j.yhbeh.2011.08.017 [PubMed] [Cross Ref]
- von der Goltz C., Koopmann A., Dinter C., Richter A., Rockenbach C., Grosshans M., et al. (2010). Orexin da leptin suna haɗi da sha'awar nicotine: hanyar haɗi tsakanin shan taba, ci da kuma sakamako. Psychoneuroendocrinology 35, 570-577 10.1016 / j.psyneuen.2009.09.005 [PubMed] [Cross Ref]
- Wang B., Ka ZB, Mai hikima RA (2009). Sake shigar da cocaine da munafuwa / hypocrisin / orexin keyi a cikin yanki na kwakwalwa: 'yancin kai daga cibiyar sadarwa na corticotropin-release. Biol. 65 masu ilimin zuciya, 857-862 10.1016 / j.biopsych.2009.01.018 [PMC free article] [PubMed] [Cross Ref]
- White CL, Ishii Y., Mendoza T., Upton N., Stasi LP, Bray GA, et al. (2005). Hanyoyin mai amfani da OX1R mai cin gashin kai game da abinci da nauyin jiki a cikin nau'i biyu na berayen da suka bambanta a cikin abin da ake iya haifar da kiba. 26 Peptides, 2331-2338 10.1016 / j.peptides.2005.03.042 [PubMed] [Cross Ref]
- Wu MF, Nienhuis R., Maid, N., Lam HA, Siegel JM (2011). Matsayin mai karɓar nau'in munafurci na 2 (Hcrt-r2) a cikin tsari na harshen hypocretin da cataplexy. J. Neurosci. 31, 6305-6310 10.1523 / JNEUROSCI.0365-11.2011 [PMC free article] [PubMed] [Cross Ref]
- Yamanaka A., Beuckmann CT, Willie JT, Hara J., Tsujino N., Mieda M., et al. (2003). Jirgin samfurin hypothalamic na ƙarancin gyare-gyare na samar da ƙanshi bisa ga daidaitaccen makamashi a cikin mice. Neuron 38, 701-713 10.1016 / S0896-6273 (03) 00331-3 [PubMed] [Cross Ref]
- Zheng H., Patterson LM, Berthoud HR (2007). Ana nuna alamar Orexin a cikin yanki na kwakwalwa na jiki don ci abinci mai ƙanshi wanda ya haifar da ƙarfin motsa jiki daga cikin ƙwayar mahaifa. J. Neurosci. 27, 11075-11082 10.1523 / JNEUROSCI.3542-07.2007 [PubMed] [Cross Ref]
- Zhu LY, Summah H., Jiang HN, Qu JM (2011). Plasma orexin-matakan da ke cikin marasa lafiya COPD tare da rashin ciwo na numfashi na hypercapnic. Mediators Inflamm. 2011, 754847 10.1155 / 2011 / 754847 [PMC free article] [PubMed] [Cross Ref]
- Zorrilla EP, Koob GF (2004). Dalili mai kyau na CRF1 antagonists don damuwa. Kwararren Kwararre. Investig. 13 Drugs, 799-828 10.1517 / 13543784.13.7.799 [PubMed] [Cross Ref]